EBO-PEP 2026 Filovirus Post-Exposure Prophylaxis, preparedness and efficacy evaluation during outbreak in Central and West-Africa
- Coordinator
- Institut National De La Sante Et De La Recherche Medicale, France
- Runs
- 1 August 2026 to 31 July 2028
- Status
- Running
- EU funding
- €12.8m
- Total cost
- €12.8m
- Partners
- 8 organisations in 4 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101355915
What the project is doing
In the project's own words, from its summary on CORDIS.
In May 2026, a Bundibugyo virus disease (BVD) outbreak was reported in Democratic Republic of Congo (DRC), highlighting the urgent need for effective medical countermeasures, as no licensed vaccine or therapeutic is currently available against this Ebola species. The EBO-PEP project was funded by EDCTP in 2024 to evaluate a post-exposure prophylaxis (PEP) strategy against Ebola virus disease (EVD). Beyond its initial objective, EBO-PEP enabled the consortium to establish a robust outbreak research platform, designed as a preparedness tool rapidly activatable across filovirus species.
The emergence of the current BVD outbreak in Eastern DRC provides the first opportunity to implement this framework. The consortium has adapted the EVD protocol to the BVD context, mobilizing the infrastructure, partnerships, and operational capacities already in place. Among the candidate interventions, obeldesivir (ODV), an orally administered broad-spectrum antiviral prioritized by the WHO R&D Blueprint, is evaluated as PEP in a randomized trial.
Remdesivir (RDV), with an established safety profile in children and pregnant women, is proposed for vulnerable populations excluded from the randomized trial. The EBO-PEP consortium brings together African and European institutions with complementary expertise in filovirus research and clinical trial implementation in outbreak settings. The overall objective of this project is to increase the portfolio of therapeutic tools against BDBV by evaluating a PEP strategy for high-risk contacts in Eastern DRC.
To address this objective, we focus our activities on two specific objectives: (i) to set up a randomized, placebo-controlled phase III clinical trial in Eastern DRC to test the efficacy of ODV used as PEP for high-risk contacts; and (ii) to set up a parallel prospective interventional cohort to generate evidence on the safety, feasibility, and effectiveness of RDV as PEP in children under 12 years and pregnant or breastfeeding women.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Coordinator |
| Institut National De Recherche Biomedicale Du Zaire | Kinshasa Gombe | CD | Participant |
| Association Pac-Ci | Abidjan | CI | Participant |
| Chu Hopitaux De Bordeaux | Talence | France | Third party |
| Sorbonne Universite | Paris | France | Third party |
| The Alliance for International Medical Action | Paris | France | Participant |
| Universite De Bordeaux | Bordeaux | France | Participant |
| Universite Cheikh Anta Diop De Dakar | Dakar Fann | SN | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI